PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of scirepAboutEditorial BoardFor AuthorsScientific Reports
 
Sci Rep. 2017; 7: 45088.
Published online 2017 March 22. doi:  10.1038/srep45088
PMCID: PMC5361167

The Immunosuppressant Mycophenolic Acid Alters Nucleotide and Lipid Metabolism in an Intestinal Cell Model

Abstract

The study objective was to elucidate the molecular mechanisms underlying the negative effects of mycophenolic acid (MPA) on human intestinal cells. Effects of MPA exposure and guanosine supplementation on nucleotide concentrations in LS180 cells were assessed using liquid chromatography-mass spectrometry. Proteomics analysis was carried out using stable isotope labeling by amino acids in cell culture combined with gel-based liquid chromatography-mass spectrometry and lipidome analysis using 1H nuclear magnetic resonance spectroscopy. Despite supplementation, depletion of guanosine nucleotides (p < 0.001 at 24 and 72 h; 5, 100, and 250 μM MPA) and upregulation of uridine and cytidine nucleotides (p < 0.001 at 24 h; 5 μM MPA) occurred after exposure to MPA. MPA significantly altered 35 proteins mainly related to nucleotide-dependent processes and lipid metabolism. Cross-reference with previous studies of MPA-associated protein changes widely corroborated these results, but showed differences that may be model- and/or method-dependent. MPA exposure increased intracellular concentrations of fatty acids, cholesterol, and phosphatidylcholine (p < 0.01 at 72 h; 100 μM MPA) which corresponded to the changes in lipid-metabolizing proteins. MPA affected intracellular nucleotide levels, nucleotide-dependent processes, expression of structural proteins, fatty acid and lipid metabolism in LS180 cells. These changes may compromise intestinal membrane integrity and contribute to gastrointestinal toxicity.

The anti-proliferative drug mycophenolic acid (MPA) is a cornerstone of most immunosuppressive regimens after solid organ transplantation1. MPA exerts its immunosuppressive properties by inhibition of inosine 5′-monophosphate dehydrogenase (IMPDH), the enzyme that limits de novo purine synthesis. Most cell types are able to replenish purine pools via a salvage and a de novo pathway. Lymphocytes, however, are almost fully dependent on purine de novo synthesis. As clonal expansion of lymphocytes is essential for an immune response, MPA inhibits precursor generation for deoxyribonucleic acid synthesis and consecutively lymphocyte proliferation, thereby effectively blocking immunoreactions. Nevertheless, gastrointestinal (GI) intolerability limits applicability of MPA-based regimens2,3,4,5,6. GI side effects are the main reason for dose changes or discontinuation, which often jeopardize short- and long-term outcomes of graft survival4,5,7,8,9,10. Abdominal pain, diarrhea, mucosal changes such as ulcers, and submucosal inflammation are common signs of MPA GI toxicity; similarities to Crohn’s disease have been demonstrated11. In individuals suffering from Crohn’s disease, bacterial invasion of the epithelium12 due to a compromised mucous layer and/or epithelial barrier triggers an inflammatory cascade11, which leads to the aforementioned symptoms.

The etiology of MPA-related GI adverse effects is not yet fully understood and the underlying molecular mechanisms have never comprehensively been studied. However, several hypotheses exist regarding the origin of MPA’s adverse effects on the GI tract. It has been suggested that the main mediators of toxicity are MPA’s acyl glucuronide metabolite (AcMPAG) and eventually the morpholino ester moiety N-(2-hydroxyethyl) morpholine, which is cleaved from the prodrug mycophenolate mofetil (MMF) to result in the active MPA13. AcMPAG can form protein adducts13,14, N-(2-hydroxyethyl) morpholine may cause local irritation of the epithelium13. Moreover, it has been hypothesized that MPA promotes inflammation by proliferation inhibition of the GI tract’s rapidly dividing epithelial cells6. This may lead to disruption of the GI barrier13 and Crohn’s disease-like symptoms. This hypothesis has been challenged as purines, released during the ingestion of cells from dietary sources, are highly abundant in the GI lumen13. Purines can enter the cell lumen via passive diffusion, by utilization of a transporter for nucleotides, or via a carrier-mediated process13.

Toxicodynamic mechanisms are not necessarily linked to a drug’s mechanism of action. Therefore, we investigated mechanisms of MPA toxicity at the cellular level in the presence of extracellular guanosine as provided under physiologic conditions in the intestinal human colon adenocarcinoma cell line LS180 by untargeted analysis of protein and metabolite changes. Compared to an in vivo system, a cellular system allows control of local drug and guanosine concentrations while avoiding secondary pathological processes, such as inflammation, which may interfere with the assessment of the underlying toxicity mechanisms in an in vivo setting. Human epithelial-like colon cancer LS180 cells were chosen based on a comprehensive literature review of available models applicable to elucidate adverse effects of drug treatment on the GI tract. Most importantly, LS180 cells express the pregnane X receptor, and are therefore able to upregulate/induce the expression of drug metabolizing enzymes as seen in vivo15.

Materials and Methods

Cell culture model

LS180 cells (ATCC, Manassas, VA; CL-187, passage number 40) were cultured and supplemented with guanosine (up to 1 mM) during MPA exposure (up to 250 μM).

Measurement of high-energy phosphate levels

Following extraction with perchloric acid, concentrations of the high-energy phosphates adenosine, guanosine, uridine, and cytidine tri-, di- and monophosphates (ATP, ADP, AMP, GTP, GDP, GMP, UTP, UDP, UMP, CTP, CDP, CMP) and the cofactors nicotinamide dinucleotide (NAD+), NAD+ phosphate (NADP+), and flavin adenine dinucleotide (FAD) were measured on an API 4000 triple quadrupole (AB Sciex, Concord, ON, Canada) by high-performance liquid chromatography-mass spectrometry (HPLC-MS)16.

SILAC, GeLC-MS, and analysis of differentially expressed proteins

Cells were labeled with heavy lysine ([U-13C6]-L-lysine) or light lysine ([12C6]-L-lysine) using Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC, Invitrogen, Carlsbad, CA). Cells were lysed and after 1D gel electrophoresis, bands were digested with trypsin. HPLC-MS analysis was performed on an LTQ-FT Ultra hybrid mass spectrometer (Thermo Scientific, San Jose, CA). Gel-based liquid chromatography-mass spectrometry (GeLC-MS) data were analyzed using the MaxQuant software package17 (Max Planck Institute of Biochemistry, Martinsried, Germany, version 1.2.2.5), the Database for Annotation, Visualization, and Integrated Discovery (DAVID)18,19 and Pathway Palette20.

Cross reference with proteome alterations in rat models and other human cell lines of non-cancerous origin

For comparison of data collected using the LS180 cell model (human colon cancer) with those collected using common rat models (Wistar rats) proteins/genes from the three available publications on this topic (kidney tissue of MMF-treated rats14, liver and colon tissue of MMF-treated rats21, analysis of gene expression (complementary deoxyribonucleic acid microarray analysis) in liver and gut of MMF-treated rats22) were pooled (Supplementary Table S1). For comparison with data collected through models using other human cell lines (HEK-293, CCRF-CEM; differential proteome analysis) protein/gene data from two available publications were pooled23,24 (Supplementary Table S2). DAVID software was used for comparison.

NMR spectroscopy analysis

Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker DRX 600 spectrometer (Bremen, Germany) and processed using MestRe-C software (version 4.9.9.9, Mestrelab Research, Santiago de Compostela, Spain). Compounds were identified by comparison of signals from 1H-13C HSQC NMR spectra to database values25,26.

All experimental procedures

For additional information and details please see the Supplementary Materials and Methods.

Statistics

Statistical significance of differences between groups was determined by one-way analysis of variance (ANOVA) combined with Scheffe’s post-hoc test. GeLC-MS data were analyzed by online tools using Benjamini and/or Bonferroni correction for multiple testing.

Results

Levels of nucleotides, cofactors, and nucleotide energy charges in LS180 cells after exposure to MPA

Although intestinal cells are known to import nucleotides from the GI lumen13, we hypothesized that MPA treatment compromises intracellular nucleotide concentrations of LS180 cells. Significant impairment of intracellular nucleotide levels despite guanosine supplementation was observed in our cell culture model (Table 1; Supplementary Figs S1 and S2). While supplementation with 200 μM and 1 mM guanosine largely restored adenosine nucleotide concentrations in LS180 cells treated with 250 μM MPA (Supplementary Fig. S1), guanosine nucleotide concentrations remained significantly lower than in controls not treated with guanosine (p < 0.001) for MPA concentrations ≥5 μM despite guanosine supplementation for 24 and 72 h (Supplementary Fig. S1). Even for LS180 cells treated with 1 mM exogenous guanosine; GTP, GDP, and GMP levels were only approximately 30% of the controls. Addition of guanosine to culture media reversed changes in UMP and UDP levels after 24 and 72 h that were observed without guanosine supplementation (Supplementary Fig. S1). UTP levels, on the other hand, were significantly higher (p < 0.01 and 0.001, respectively) after exposure to MPA concentrations ≥5 μM and in the presence of 200 μM and 1 mM guanosine after 72 h. In most cases, changes in cytidine nucleotide levels were reversed by supplementation with guanosine (Supplementary Fig. S2). Slightly elevated values suggest imbalances in cytidine nucleotide levels in LS180 cells despite of, or possibly due to, guanosine supplementation of the culture media. Disturbances in NAD+, NADP+, and FAD concentrations, which mainly occurred after 72 h of exposure to higher MPA concentrations in the absence of guanosine supplementation, were similar to control levels when incubation media were supplemented with guanosine (Supplementary Fig. 2). While nucleotide energy charges in MPA-treated cells did not show marked differences compared to control cells with guanosine supplementation <1 mM, uridylate energy charges after 72 h of treatment with 250 μM MPA and 1 mM guanosine increased remarkably (125.3 ± 5.0% of controls, p < 0.05, Supplementary Fig. S2). In summary, some negative effects of MPA on nucleotide levels were partially or fully reversed by supplementation with guanosine. Despite supplementation with 1 mM guanosine, levels of all guanosine nucleotides were significantly decreased (p < 0.001) and levels of uridine and cytidine nucleotides were upregulated with consequent effects on the uridylate energy charge. Levels of the second messenger cyclic adenosine monophosphate and cyclic guanosine monophosphate were mostly unaffected by MPA, regardless of exogenous guanosine concentrations (Supplementary Fig. 3), when examined by enzyme-linked immunosorbent assays.

Table 1
Summary of concentration-dependent effects of exogenous guanosine on nucleotide levels and energy charges of LS180 cells exposed to increasing concentrations of MPA.

Investigation of proteome alterations in LS180 cells after exposure to MPA and cross reference of results with proteome alterations in rat models and other human cell lines of non-cancerous origin

Expression levels of 35 proteins were significantly changed (p < 0.05, >1.2-fold) in MPA-treated LS180 cells despite supplementation with 1 mM guanosine as identified by SILAC in combination with GeLC-MS (Table 2). As a representative example, HPLC-MS data for the VIILMDPFDDDLK peptide, one of the unique peptides that served to identify the protein long-chain acyl-coenzyme A synthetase 5 (ACSL5) is shown in Supplementary Fig. S4). Functional annotation clustering of the 35 affected proteins using DAVID software yielded the four annotation clusters “guanyl nucleotide-binding”, “lipid catabolic process”, “protein polymerization”, and “mitochondrial membrane” (enrichment scores >2.7, Supplementary Table S3). Analysis using additional gene ontology tools repeatedly indicated links to purine/lipid metabolism as well as the subcellular compartments mitochondria and cytoskeleton (functional annotation chart, pathway enrichment analysis, and functional annotation classification; please see Supplementary Tables S4–S6, respectively).

Table 2
LS180 cell proteins with changes >20% after exposure of cells to MPA as identified by SILAC in combination with GeLC-MS.

Affected proteins were mapped to KEGG pathways (Supplementary Figs S5 and S6) illustrating dysregulation of fatty acid degradation and synthesis during MPA exposure (Supplementary Figs S5 and S6). DAVID analysis of data from rat models pooled form the literature14,21,22 showed effects of MPA on “carbohydrate catabolic processes” and “nucleotide/purine nucleotide metabolic processes” as well as on pathways of carbohydrate and amino acid metabolism (functional annotation clustering and pathway enrichment analysis, please see Supplementary Tables S7 and S8, respectively). Analysis of proteins/genes that were affected by MPA treatment in other human cell types (HEK-293 and CCRF-CEM26,27) did not yield any significantly enriched annotation terms or pathways.

A protein-protein interaction network was generated from the 13 proteins of significantly enriched KEGG functional categories (EASE score <0.5), i.e. ACSL5, acetyl-coenzyme A acetyltransferase (ACAT2), very long-chain specific acyl-coenzyme A dehydrogenase (VLCAD), peroxisomal acyl-coenzyme A oxidase 1 (AOX), trifunctional enzyme subunit α (TFP), acetyl-coenzyme A acyltransferase (ACAA2), dihydrolipoamide dehydrogenase (DLD), tubulin α-1C chain (TUBA1C), tubulin α-4A chain (TUBA4A), tubulin β-4A chain (TUBB4A), tubulin β chain (TUBB), succinyl-coenzyme A ligase [ADP/GDP-forming] subunit α (SCS-α), and fatty acid-binding protein 1 (FABP1) with the purpose of identifying additional potentially affected proteins. The protein-protein interaction network generated based on the BioGrid database (Fig. 1, Panel a) and Human Protein Reference Database (Fig. 1, Panel b) revealed 18 and 55 first-order direct neighbors with more than two interactions, respectively. First-order direct neighbors were sorted based on number of interactions with differentially expressed proteins (Supplementary Table S9). Candidate proteins to be affected by MPA (chosen based on biological/metabolic proximity to differentially expressed proteins and/or interactions with multiple differentially expressed proteins) were interrogated by Western blot analysis, but no differences in protein expression for representative proteins were found.

Figure 1
Network of proteins of enriched pathways and first-order shared neighbors constructed using the Pathway Palette software.

Western blot analysis

Western blot analysis was carried out for five representative proteins to verify SILAC GeLC-MS results, namely ACSL5 (increased), annexin A1 (ANXA1; increased), solute carrier family 12 member 2 (SLC12A2, decreased), polymeric immunoglobulin receptor (PIgR, decreased), and regenerating islet-derived protein 4 (REG-4; decreased; Fig. 2, Panel a and b), but SILAC results could only partially be confirmed. Two western blots for ACSL5, conducted with different antibodies raised against different epitopes, showed differential ACSL5 expression. While analysis using the first antibody (Sigma, WH0051703M1) showed no significant change for ACSL5 expression for MPA-treated LS180 cells, analysis using the second antibody (Abcam, ab104892) showed significant decreases of ACSL5 for treatment with 100 μM (p < 0.05) and 250 μM (p < 0.001) MPA. To illustrate these findings and visualize the discrepancy between MS and western blot results as well as western blot results using the two different antibodies, the ACSL5 amino acid sequence is listed in Fig. 2, Panel c; unique peptides and epitopes are indicated.

Figure 2
Interrogation of SILAC GeLC-MS results by Western blot analysis.

In addition, levels of protein expression were investigated by western blot analysis for three representative proteins identified by Pathway Palette analysis as first-order direct neighbors and therefore potentially affected due to metabolic proximity to altered proteins as identified by SILAC and GeLC-MS, i.e. tight junction protein ZO-1 (ZO-1), 14-3-3 protein θ (14-3-3 θ; simultaneous identification by BioGRID and Human Protein Reference Database (HPRD) databases), and polyubiquitin-C (UBC; 9 interactions assigned by BioGRID). No differences in expression levels of these proteins were found (Fig. 2, Panel d and e).

Quantitative 1H-NMR spectroscopy of lipid extracts of LS180 cell

After confirmation of signal assignments by 2D NMR experiments (Fig. 3, Panel a, b, and c), quantification of abundant compounds revealed increases (p < 0.05 or p < 0.01) in cholesterol/cholesterol esters (Chol C19), fatty acids (Fα, Fβ, Fω, F(CH2)x + Fω−1), and phosphatidylcholines (PtdCho α/β), after exposure to 100 μM MPA and 1 mM guanosine supplementation (Fig. 3, Panel d). Trimethylammonium compounds/choline head groups (N+(CH3)3), diacylglycerols (DAG β), riacylglycerols (TAG β), carbon atoms at a double bond (FΔ-1, monounsaturated fatty acids (MUFA)), polyunsaturated fatty acids (FΔ-CH2-Δ, PUFA), and total number of double bonds (TDB, MUFA+PUFA) were unchanged.

Figure 3
NMR spectra of a lipophilic LS180 cell extract.

Discussion

The most important molecular mechanisms of mycophenolate intestinal toxicity described in the literature, as of today, are limited to the covalent binding of the acyl glucuronide metabolite of MPA (AcMPAG) to various intestinal proteins21 and the disruption of tight junctions27. Two follow up studies showed that the disruption of intestinal tight junctions was associated with chromatin histone modifications, including an increase in midkine concentrations28,29. In contrast to these targeted studies, as aforementioned, in the present study, we took a comprehensive, non-targeted, unique combined proteo-metabolomic approach that resulted in a much more complete picture of the time- and dose-dependent effects of mycophenolic acid on intestinal cell protein concentrations and cell metabolism at various levels of guanosine supplementation.

The gastrointestinal epithelium is locally exposed to high MPA concentrations, especially at the locations where MMF/MPA is released from the formulation, which are in the range of the concentrations tested in the present study. Other studies used MPA at lower concentrations (e.g. 0.1–5 μM30, 10 μM31) in vitro than the present study and guanosine concentrations necessary to reverse MPA-induced effects were around 50–100 μM30,31. Such studies evaluated inhibition of cell proliferation, which depends on availability of guanosine nucleotides, but does not necessarily reflect levels of intracellular guanosine pools and the concentrations present at the intestinal epithelium. Due to the differences in MPA and guanosine concentrations, our results cannot directly be compared to such previous studies. As in the present study supplementation even with concentrations as high as 1 mM guanosine could not restore guanosine nucleotide levels, it is likely that a similar dysregulation of nucleotides occurs intracellularly in vivo. In particular GDP-, UDP-, and CDP-linked intermediates play a key role in lipid metabolism, membrane synthesis, and protein glycosylation32,33, suggesting negative effects of MPA on epithelial barriers.

Binding of guanosine nucleotides was associated with the function of eight of the 35 differentially expressed proteins in LS180 cells (Supplementary Table S4, #1: “guanyl nucleotide-binding”). Effects of MPA have been attributed to intracellular guanosine nucleotide depletion34,35,36,37, e.g. changes in protein glycosylation especially studied with respect to modifications of adhesion molecules36,37. Nevertheless, the notion that intracellular guanosine nucleotides in GI epithelial cells are abundant due to import of guanosine from the intestinal lumen so that MPA-mediated inhibition of de novo synthesis of GTP has little or no effect13, is not confirmed by the present study.

Effects of MPA and its metabolite AcMPAG on tubulin polymerization (even in the presence of exogenous GTP) have been described by Feichtinger et al.37. Effects on tubulins were also seen in LS180 cells; tubulin subunits constitute 50% of proteins of group #1 (“guanyl nucleotide-binding”) and 100% of proteins of group #3 (“protein polymerization”). Interestingly, potentially affected proteins identified by Pathway Palette are also linked to enriched functions/annotation terms (i.e. regulation of cell cycle, signaling processes, transcription, tight junctions, cytoskeletal properties, and transport; Supplementary Table S3).

Feichtinger et al.37 reported induction of tubulin polymerization, while in the present study the cellular amount of four tubulin subunits was decreased to 74.0–79.2% of control values in LS180 cells treated with 250 μM MPA (Table 2). Morath et al., on the other hand, found cytoskeletal proteins (vinculin, tubulin) to be downregulated in human fibroblasts, suggesting that MPA exposure results in cytoskeletal dysfunction15. Literature on MPA’s effect on lipid and fatty acid metabolism is scarce38. However, clinical studies show association of MMF and hyperlipidemia38, which is in accordance with our findings that expression of four proteins attributed to the term “Lipid catabolic process” (Supplementary Table S3) were significantly increased. Conversely, no significant changes occurred in serum cholesterol or triglyceride levels of rabbits on high-cholesterol diets with or without MMF in a study by Subramanian et al.38.

Data from studies involving LS180 cells differ from corresponding rat model data (Supplementary Table S5 vs. S8). These differences are likely due to differences in model systems (in vitro vs. in vivo), species (human vs. rat), doses, platforms, and data analysis methods. Comparing proteomics data in the present study with data of MMF treatment of rats (#1 in Supplementary Table S5 vs. #6 in Supplementary Table S8), four proteins involved in fatty acid metabolism were affected in rats, but Functional Annotation Clustering of rat model data (Supplementary Table S7) yielded only clusters related to carbohydrate or nucleotide processes. Sufficient data on MPA’s effects on glucose metabolism is lacking38. No effects of MMF on glucose metabolism were observed in clinical trials and effects of MMF on insulin secretion and insulin gene expression seem to differ between species in vitro (MMF inhibits insulin secretion in rat islets39, but does not show effects on insulin secretion or insulin gene expression in human islets40). Although multiple other factors such as the cancerous nature of LS180 cells, methodological differences, and sample size may have an effect, this pattern can be traced when comparing the present results from the LS180 cell model with in vivo data from rat models. As shown in Supplementary Table S7 (rat), the term “carbohydrate catabolic process” is listed as the most enriched term, but is not listed among Functional Annotation Clusters from analysis of LS180 cell data (Supplementary Table S3). Pathway Enrichment Analyses of 35 proteins in LS180 cells affected by MPA exposure and 76 proteins/genes affected by MPA exposure in rats (Supplementary Table S3) show the same model-dependent pattern using the KEGG database and DAVID’s Functional Annotation Chart tool (Supplementary Table S5 vs. S8). For LS180 cells, several of the listed terms were linked to lipid metabolism (e.g. #1: fatty acid metabolism, #5: propanoate metabolism, #6: fatty acid elongation in mitochondria, #7: peroxisome proliferator-activated receptor (PPAR) signaling pathway; Supplementary Figs S5 and S6). Analysis of rat proteome data revealed several enriched terms linked to lipid metabolism (#4: propanoate metabolism, #6: fatty acid metabolism, #11: butanoate metabolism). On the other hand, alterations in the expression of proteins involved in glucose and protein metabolism/amino acid degradation were primarily observed in rats undergoing MMF treatment (i.e. #1: glycolysis/gluconeogenesis, #2: pyruvate metabolism, #3: arginine and proline metabolism, #7: tryptophan metabolism, #8: phenylalanine metabolism, #10: fructose and mannose metabolism), while only two pathways involved in amino acid degradation were significantly affected in LS180 cells (i.e. #2: valine, leucine, and isoleucine degradation, #5: propanoate metabolism).

To corroborate an increase in ACSL5 observed in the SILAC proteomics experiment after exposure of LS180 cells to MPA, samples were also analyzed using western blot. At first only a small, non-significant change in expression levels was found. Nevertheless, repeat analysis using a different antibody showed a marked decrease in ACSL5 protein levels after exposure to 100 μM and 250 μM MPA (66.4 ± 8.3% and 8.7 ± 1.2% of controls). Only unmodified peptides and standard variable modifications were included for protein quantification in MaxQuant. The approximately 2-fold increase in ACSL5 assessed in SILAC GeLC-MS experiments related to these unmodified peptides. The decrease seen in western blots using the second anti-ACSL5 antibody was likely due to a modification of the antibody binding site (marked in blue in the ACSL5 amino acid sequence in Fig. 2, Panel c), as this site is not part of a unique peptide that served for protein identification (marked in bold and brackets in Fig. 2, Panel c).

Moreover, compared to controls, UTP and GTP levels were dysregulated in MPA-treated LS180 cells despite supplementation with 1 mM guanosine. Nucleotides are intermediates in the glycosylation of proteins and lipids41,42: glucose, galactose, and various amines are transferred to proteins via UDP intermediates, fucose and mannose are transferred via GDP. Although MPA induces inhibition of glycosylation of proteins through depletion of guanosine nucleotides12,43, augmentation of glycosylation in LS180 cells may occur due to increased UTP (Supplementary Fig. S1).

While increases in ANXA1 expression during MPA exposure as observed in the SILAC proteomics analysis could be verified by western blot (Fig. 2, Panel a and b), no changes in SLC12A2, PIgR, and REG-4 expression were detected by western blot. Nevertheless, for the following reasons, this does not preclude the SILAC GeLC-MS results from being correct. As discussed for the ACSL5 western blot results, the generally semi-quantitative nature of western blot analyses and MPA’s known ability to strongly influence protein glycosylation may have compromised the western blot analysis. Moreover, the results from nucleotide HPLC-MS, DAVID, and NMR-based metabolomics analyses and the literature22 support that MPA indeed affects SLC12A2 and PIgR expression.

The majority of affected proteins (Table 2) is involved in lipid metabolism. Proteins of “Fatty acid metabolism”, “Fatty acid elongation in mitochondria” (Supplementary Table S5), and “Lipid catabolic processes” (Supplementary Table S3 and S6) were significantly upregulated in LS180 cells after MPA treatment (with the exemption of ACAT2, which was downregulated). The term “mitochondrial membrane” (Supplementary Table S3) lists almost exclusively proteins that were found to be increased (with the exemption of SCS-α, which was downregulated). These results also suggested imbalances in membrane composition.

To further examine the impact of changes in the expression of proteins involved in lipid metabolism, intra- cellular lipid patterns were assessed using an 1H-NMR-based metabolomics approach. Cholesterol is a precursor for signaling molecules and is a fundamental constituent of cell membranes44 and changes of its intracellular levels may mediate drug toxicity. With the observed increases in phosphatidylcholines and cholesterol levels, homeostasis of two major membrane constituents is affected in LS180 cells exposed to MPA. In fact, phosphatidylcholines are the most prominent membrane phospholipids and crucial for maintenance of GI barrier function45. Intracellular phosphatidylcholines are secreted by epithelial cells and passaged across tight junctions into the apical mucus layer46, where they contribute to the establishment of a hydrophobic surface of the colonic mucus layer45. In the plasma membrane of enterocytes, phosphatidylcholine modulates the mucosal signaling state as lipid composition of membranes is a regulatory parameter of inflammatory responses45. Decreased levels of luminal phosphatidylcholines in colonic mucus have been linked repeatedly to ulcerative colitis, an inflammatory bowel disease similar to Crohn’s disease45,46, but this finding does not apply to Crohn’s disease patients47,48. Upregulation of intracellular phosphatidylcholines in MPA-treated LS180 cells suggests disturbances of lipid levels linked to mucosal defense. Phosphatidylcholine is synthesized from choline via the Kennedy-pathway involving cytidine nucleotides49. Phosphocholine and CTP are formed from CDP-choline and pyrophosphate, consecutively CDP-choline and diacylglycerol (or alkyl-acylglycerol) are converted to phosphatidylcholine (with CMP as byproduct). Slightly elevated levels of cytidine nucleotides observed at 72 h with 100 μM MPA and 1 mM guanosine (Supplementary Fig. S2, Table 1) may be associated with increased phosphatidylcholine biosynthesis. Furthermore, increases in fatty acid, diacylglycerol, and triacylglycerol may also be related to impaired composition of membrane lipids, e.g. other phospholipids than phosphatidylcholines, which constitute membranes50.

The major limitation of this study is the use of a cancer cell line and the associated potential differences in metabolism, protein expression and their regulation compared to normal human intestinal cells. Nevertheless, as aforementioned, the results of the present study were cross-referenced to currently available proteomics data on MPA toxicity in rat models and other human cell culture models using cells of non-cancerous origin using DAVID (pathway enrichment analysis using KEGG). Overlap of the results with those of the present study support the validity of the LS 180 cell model. Although it was not our objective to validate the LS180 cells culture model, the results of the present study are further proof that LS180 cells are an attractive model as a fast and simple screen for potential intestinal toxicity of drugs and drug candidates beyond MPA and are an alternative to more cumbersome but widely used Caco-2 cell models. An interesting question is if, and how, the observed proteomics and metabolomics changes are associated with impairment of the intestinal barrier. The present study was not designed to assess this question and this will be evaluated in a follow up.

In conclusion, the present study based on the LS180 cell model and a metabolomics-proteomics profiling strategy suggests that MPA-induced GI disturbances involve the dysregulation of nucleotide-dependent processes and lipid metabolism. Our data support that MPA’s GI toxicity is linked to the drug’s mechanism of action resulting in disturbance of intracellular guanosine levels, that are important not only for cell proliferation but also other vital intracellular processes. Importantly, the results of the present study suggested that, other than hypothesized, guanosine supplementation does not fully reverse the negative effects of MPA on nucleotide metabolism. The negative effects of MPA in the present study were concentration-dependent suggesting that the avoidance of high local concentrations in the intestine, for example by the development of sustained release formulations, may improve its GI tolerability.

Additional Information

How to cite this article: Heischmann, S. et al. The Immunosuppressant Mycophenolic Acid Alters Nucleotide and Lipid Metabolism in an Intestinal Cell Model. Sci. Rep. 7, 45088; doi: 10.1038/srep45088 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Supplementary Dataset 1:
Supplementary Dataset 2:

Footnotes

The authors declare no competing financial interests.

Author Contributions Experimental design: S.H. and U.C.; Performance of experiments: S.H. and M.D.; Data analysis: S.H. and M.D.; Administrative, technical, and/or material support: U.C., D.L., K.H.; Writing of Manuscript: S.H. and U.C. All authors have read and approved the manuscript for publication.

References

  • Bardsley-Elliot A., Noble S. & Foster R. H. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation. BioDrugs 12, 363–410 (1999). [PubMed]
  • Budde K., Durr M., Liefeldt L., Neumayer H. H. & Glander P. Enteric-coated mycophenolate sodium. Expert Opin. Drug. Saf. 9, 981–994 (2010). [PubMed]
  • Shipkova M., Armstrong V. W., Oellerich M. & Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin. Drug. Metab. Toxicol. 1, 505–526 (2005). [PubMed]
  • Bunnapradist S. et al. . Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82, 102–107 (2006). [PubMed]
  • Bunnapradist S. & Ambuhl P. M. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin. Transplant. 22, 815–821 (2008). [PubMed]
  • Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 24, 645–663 (2001). [PubMed]
  • Pelletier R. P. et al. . The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin. Transplant. 17, 200–205 (2003). [PubMed]
  • Tierce J. C., Porterfield-Baxa J., Petrilla A. A., Kilburg A. & Ferguson R. M. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin. Transplant. 19, 779–784 (2005). [PubMed]
  • Legorreta A. P. et al. . Linking gastrointestinal events, mycophenolate mofetil dose reduction and discontinuation, graft outcomes, and healthcare costs in renal transplant recipients. Transpl. Int. 20, 136–136 (2007).
  • Hardinger K. L., Brennan D. C., Lowell J. & Schnitzler M. A. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl. Int. 17, 609–616 (2004). [PubMed]
  • Di Sabatino A., Rovedatti L., Vidali F., Macdonald T. T. & Corazza G. R. Recent advances in understanding Crohn’s disease. Intern. Emerg. Med. 8, 101–113 (2013). [PubMed]
  • Swidsinski A., Loening-Baucke V. & Herber A. Mucosal flora in Crohn’s disease and ulcerative colitis - an overview. J. Physiol. Pharmacol. 60, Suppl. 6 61–71 (2009). [PubMed]
  • Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant. Proc. 39, 88–93 (2007). [PubMed]
  • Asif A. R. et al. . Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. Biochimie 89, 393–402 (2007). [PubMed]
  • Pfrunder A., Gutmann H., Beglinger C. & Drewe J. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J. Pharm. Pharmacol. 55, 59–66 (2003). [PubMed]
  • Klawitter J., Schmitz V., Klawitter J., Leibfritz D. & Christians U. Development and validation of an assay for the quantification of 11 nucleotides using LC/LC-electrospray ionization-MS. Anal. Biochem. 365, 230–239 (2007). [PubMed]
  • Cox J. et al. . A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat. Protoc. 4, 698–705 (2009). [PubMed]
  • Huang da W., Sherman B. T. & Lempicki R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009). [PubMed]
  • Huang da W., Sherman B. T. & Lempicki R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009). [PMC free article] [PubMed]
  • Askenazi M., Li S., Singh S. & Marto J. A. Pathway Palette: a rich internet application for peptide-, protein- and network-oriented analysis of MS data. Proteomics 10, 1880–1885 (2010). [PMC free article] [PubMed]
  • Shipkova M. et al. . Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics 4, 2728–2738 (2004). [PubMed]
  • Shipkova M. et al. . cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation 78, 1145–1152 (2004). [PubMed]
  • Qasim M., Rahman H., Oellerich M. & Asif A. R. Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycophenolic acid treatment. Proteome Sci. 9, 57 (2011). [PMC free article] [PubMed]
  • Heller T. et al. . Differential proteomic analysis of lymphocytes treated with mycophenolic acid reveals caspase 3-induced cleavage of rho GDP dissociation inhibitor 2. Ther. Drug Monit. 31, 211–217 (2009). [PubMed]
  • Willker W. Metabolite Assignment. University of Bremen, Germany. http://www-user.uni-bremen.de/wie/ww_metab.html (Accessed Oct 2012, service discontinued June 1, 2016).
  • Wishart D. S. Human Metabolome Database (HMDB), version 3.6. http://www.hmdb.ca (Accessed April 2015).
  • Qasim M., Rahman H., Ahmed R., Oellerich M. & Asif A. R. Mycophenolic acid mediated disruption of the intestinal epithelial tight junctions. Exp. Cell Res. 322, 277–289 (2014). [PubMed]
  • Khan N., Pantakani D. V., Binder L., Qasim M. & Asif A. R. Immunosuppressant MPA modulates tight junction through epigenetic activation of MLCK/MLC-2 pathway via p38MAPK. Front. Physiol. 6, 381 (2015). [PMC free article] [PubMed]
  • Khan N., Lenz C., Binder L., Pantakani D. V. & Asif A. R. Active and repressive chromatin-associated proteome after MPA treatment and the role of midkine in epithelial monolayer permeability. Int. J. Mol. Sci. 17, pii E597 (2016). [PMC free article] [PubMed]
  • Daxecker H., Raab M., Cichna M., Markl P. & Mueller M. M. Determination of the effects of mycophenolic acid on the nucleotide pool of human peripheral blood mononuclear cells in vitro by high-performance liquid chromatography. Clin. Chim. Acta 310, 81–87 (2001). [PubMed]
  • Sokoloski J. A. & Sartorelli A. C. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism. Mol. Pharmacol. 28, 567–573 (1985). [PubMed]
  • Cansev M. Uridine and cytidine in the brain: their transport and utilization. Brain Res. Rev. 52, 389–397 (2006). [PubMed]
  • Qiu Y. et al. . Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes. Transplantation 69, 890–897 (2000). [PubMed]
  • Messina E. et al. . Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int. J. Cancer 108, 812–817 (2004). [PubMed]
  • Cass C. E., Lowe J. K., Manchak J. M. & Henderson J. F. Biological effects of inhibition of guanine nucleotide synthesis by mycophenolic acid in cultured neuroblastoma cells. Cancer Res. 37, 3314–3320 (1977). [PubMed]
  • Raab M. et al. . In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells. Clin. Chim. Acta 310, 89–98 (2001). [PubMed]
  • Jepson S., Brogan I. J., Stoddart R. W. & Hutchinson I. V. Mycophenolic acid does not inhibit protein glycosylation in T lymphocytes. Transpl. Immunol. 8, 169–175 (2000). [PubMed]
  • Subramanian S. & Trence D. L. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol. Metab. Clin. North Am. 36, 891–905 (2007). [PubMed]
  • Li G. et al. . Prolonged depletion of guanosine triphosphate induces death of insulin-secreting cells by apoptosis. Endocrinology 139, 3752–3762 (1998). [PubMed]
  • Polastri L. et al. . Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol. 39, 229–233 (2002). [PubMed]
  • Allison A. C. & Eugui E. M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47, 85–118 (2000). [PubMed]
  • Wellen K. E. & Thompson C. B. A two-way street: reciprocal regulation of metabolism and signalling. Nat. Rev. Mol. Cell Biol. 13, 270–276 (2012). [PubMed]
  • Christians U. et al. . Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges. Ther. Drug Monit. 30, 151–158 (2008). [PubMed]
  • de Boussac H. et al. . LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly. Am. J. Cancer Res. 3, 58–69 (2013). [PMC free article] [PubMed]
  • Ehehalt R., Braun A., Karner M., Fuellekrug J. & Stremmel W. Phosphatidylcholine as a constituent in the colonic mucosal barrier–physiological and clinical relevance. Biochim. Biophys. Acta. 1801, 983–993 (2010). [PubMed]
  • Gotthardt D. et al. . Separate basolateral and apical phosphatidylcholine secretion routes in intestinally differentiated tumor cells. World J. Gastroenterol. 15, 5821–5826 (2009). [PMC free article] [PubMed]
  • Stremmel W., Hanemann A., Ehehalt R., Karner M. & Braun A. Phosphatidylcholine (lecithin) and the mucus layer: Evidence of therapeutic efficacy in ulcerative colitis? Dig. Dis. 28, 490–496 (2010). [PubMed]
  • Braun A. et al. . Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm. Bowel Dis. 15, 1705–1720 (2009). [PubMed]
  • Gibellini F. & Smith T. K. The Kennedy pathway–De novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life 62, 414–428 (2010). [PubMed]
  • Kahle M. et al. . High fat diet-induced modifications in membrane lipid and mitochondrial-membrane protein signatures precede the development of hepatic insulin resistance in mice. Mol. Metab. 4, 39–50 (2015). [PMC free article] [PubMed]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group